Detall de la convocatòria

Característiques

Característica
Objectiu de la convocatòria
Bill Gates and ADDF co-founder Leonard Lauder are partnering and adopting a new approach that brings together philanthropic capital with a venture mindset to advance bold new ideas for easier and more accurate diagnosis of Alzheimer's disease and related dementias.
Característiques principals
Diagnostics Accelerator is a partnership of funders dedicated to accelerating the development of affordable and accessible biomarkers to diagnose Alzheimer's disease and related dementias, and to advance the development of more targeted treatments. Through translational research awards and access to consulting support from industry experts, this program will challenge the research community to develop novel biomarkers from peripheral modalities. Peripherally-sourced biomarkers will enable greater patient tolerability, integration with existing sample testing infrastructure, and the scalability and affordability necessary for population-level screening.

Two types of projects will be supported through this RFP:
  • Proof-of-principle awards will support exploratory analyses of biomarkers at a small scale (e.g., 50-100 human samples)
  • Validation awards will support biomarkers that need to be tested at a larger scale (e.g., 500-1000 samples)

    Projects that succeed in the proof-of-principle stage may be eligible for follow-on funding in the form of a validation award.
    • Lloc de presentació
    El personal de l'IMIM i PSMAR que necessiteu més informació adreceu-vos a:
    Servei de Recerca. C/ Doctor Aiguader, 88. 08003-Barcelona. Tel.: 93.316.05.76.
    Marta López: mlopez4@imim.es Ext.: 1576
    Carol Barnwell: cbarnwell@imim.es Ext.: 1670
    Convocatòria (URL)
    https://www.alzdiscovery.org/research-and-grants/funding-opportunities/diagnostics-accelerator
    Applications:
    https://addf.fluxx.io/
    Requisits
    Funding is open to researchers and clinicians worldwide at:
  • Academic medical centers and universities or nonprofits. Industry partnerships are strongly encouraged.
  • Biotechnology companies. Funding is provided through mission-related investments that require return on investment. Existing companies and new spinouts are both eligible.
    • Dotació
  • Proof-of-principle awards: up to $500,000
  • Validation awards: Award amounts will be based on stage and scope of research.
    • AVÍS IMPORTANT
    The deadline for applications is November 16, 2018. Submission of a Letter of Intent (LOI) is required on or before September 14, 2018. LOIs are reviewed on a rolling basis and can be submitted any time prior to the deadline.

    Arxius

    Arxiu
    Diagnostics Accelerator_ Application Instructions _ Alzheimer's Drug Discovery Foundation.pdf
    Funding Opportunities_ Application & Funding Policies _ Alzheimer's Drug Discovery Foundation.pdf
    Diagnostics Accelerator_ Peripheral Biomarkers Program _ Alzheimer's Drug Discovery Foundation.pdf